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Medicinal Chemistry & Drug Discovery
Zwitterionic Surfactant as a Promising Non-Cytotoxic
Carrier for Nanoemulsion-Based Vaccine Development
Somnath Bhattacharjee,*[a, b] Jesse Chen,[b] Jeffrey Landers,[b] and James R. Baker, Jr.*[a, b]
Motivated by the lack of noncytotoxic carriers in the current
vaccine, we pursued the possibility of using a zwitterionic
surfactant as a carrier to improve their delivery efficiency with
antigen for a nanoemulsion-based vaccine. We identified that a
nanoemulsion formulation that consists of a specific zwitter-
ionic surfactant can effectively mediate cellular uptake of
antigen despite not having cytotoxicity as compared to a
nanoemulsion that consists of a cationic surfactant. We report
here the first study of a zwitterionic surfactant that consists of a
positive charge in the outer layer of the polar head group and
a hydrophobic tail is a promising approach for enhancing the
carrier’s efficacy with no noticeable toxicity under experimental
condition. However, zwitterionic surfactant that has positive
charge in the outer layer with additional hydrophobicity due to
the presence of aromatic ring had minimal cellular uptake and
transfection efficacy.
The mucosal route of vaccination has benefits over intra-
muscular (IM) and subcutaneous administration. One benefit is
its potential to induce mucosal immunity against respiratory
and gastrointestinal infections at the point of the pathogens
entry.[1] It has also been shown that mucosal immunization can
cause protective immunity at distant mucosal surfaces.[2] Given
this, the nasal cavity is a leading site for mucosal vaccination
due to its accessibility and its moderately permeable epithe-
lium which permits access to immune-reactive sites.[3,4] Unfortu-
nately, safe and effective carriers for nanoemulsion (NE) based
vaccines have been difficult to identify.
Nanoemulsion based carriers are promising candidates
under development as nasal vaccine carriers. NE provides
enhanced mucoadhesion leading to longer retention of
antigens in the nasal mucosa. NEs facilitate antigen permeation
across the mucous layer and enhance cellular uptake. NEs are
nanometer scale (d=200–700 nm) oil-in-water emulsions con-
sisting of a combination of nonionic and ionic surfactants, a co-
solvent (ethanol), oil (soybean oil), and water.[5] Prior work by
our group has produced a number of NE formulations by
varying the combinations of nonionic and ionic surfactants,
which were chosen based on their hydrophilic   lipophilic
balance (HLB) values and differing polar head groups.[6] A
typical NE formulation consists of the nonionic surfactant
Tween80 and the cationic surfactant cetylpyridinium chloride
(CPC). This formulation has demonstrated effective nano-
emulsion based adjuvant activity for a variety of antigens and
has induced systemic antibody titers comparable to injected
aluminium-based vaccines.[7] Despite their utility, cationic
surfactants including CPC usually are associated with cytotox-
icity and also cations have short in vivo circulation half life.[8]
While in some cases this is thought to be inherent to carrier
activity, we sought to develop a compound that imparts the
effects of a cationic charge while keeping it nontoxic by
polarizing the molecule so that it could be used as an effective
carrier or co-carrier along with other known adjuvants to
enhance delivery efficacy with antigen.
This led us to explore nanoparticles with zwitterionic (ZI)
surfaces. ZI particles have been shown to exhibit a long
circulatory half-life,[8b] enhance enzyme activity,[9] and demon-
strate low toxicity in cell-based assays.[10] Recently, a mannosy-
lated ZI-based cationic liposome was designed as a DNA
vaccine delivery system to promote immunogenicity with lower
cytotoxicity.[11] Interestingly, ZI polysaccharides without subse-
quent modification were successfully used as carriers.[12]
Inclusion of ZIs were found to be significantly advantageous in
both studies.[11–12] A different study identified that subtle tuning
of the head group charge orientation of ZIs resulted in
significant alterations of their activities.[13] These reports
suggest that ZIs with a positive outer layer showed superior
antimicrobial properties than similar ZIs with negative outer
layers.[13] Motivated by these reports, we hypothesize that ZIs
could be substituted for cationic surfactants in biological
applications with potentially less toxicity.
Our objective is twofold: First, we pursued the possibility
that ZIs could be used as a nontoxic alternative to cationic
surfactants in NE carriers for both DNA and protein-based
vaccines. Second, we sought to evaluate the effect of changing
the structure and charge orientations of ZIs on NE activity as a
carrier. In this study, four ZI molecules were designed,
synthesized and compared with a commercially available
cationic surfactant that has been used previously as a carrier in
NE formulations.[6] These small ZI molecules consist of different
charge orientations (Figure 1). Among the four ZI molecules,
three have positive charges on the outer layer, while the fourth
has a positive charge inside. We performed cytotoxicity, bind-
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ing, transfection, and uptake studies with NE formulations (NEs
1–5) containing these molecules (compounds 1–5). The result
showed NEs 1–5 significantly differ from each other in size, ζ-
potential and cytotoxicity. Results also suggest that substitut-
ing the small molecule consisting of hydrophobic tails and a ZI
head with positive charges in the outer layer could improve
the plasmid and ovalbumin antigen (OVA) binding capability,
antigen uptake and transfection efficacy of NE without any
noticeable cytotoxicity under experimental conditions.
We designed and synthesized ZI surfactants that consist of
either positive charges in the outer or inside layer of the
hydrophilic head group. The overall length of hydrophobic
chains in all synthesized compounds are similar to CPC, the
cationic surfactant we wished to replace. Compounds 1, 3 and
4 have similar head groups. However, head groups on
compounds 1 and 4 have reversed charge orientations.
Compound 3 consists of a positively charged group in the
outer layer and an aromatic ring that increases the hydro-
phobicity of the head group compared to compounds 1 and 4.
Compounds 2 and 5 contain phosphorylcholine (ZI) and
pyridine (cationic) head groups respectively while compound 2
(ZI) also has a positive charge in the outer layer.
Compounds 1 and 2 were synthesized as described
previously.[14] Compound 3 was synthesized in two steps as
shown in Scheme 1A. First, 4-(hexadecyloxy)benzenesulfona-
mide was synthesized by reacting 1-iodohexadecane and 4-
hydroxybenzenesulfonamide in the presence of K2CO3. Sub-
sequently, 4-(hexadecyloxy)benzenesulfonamide and (3-carbox-
ypropyl)trimethylammonium chloride were refluxed in acetone
in the presence of KI to yield compound 3.[15] N-acylsulfona-
mides are typically synthesized in the presence of DCC and
DMAP. However, compound 3 was not obtained under this
condition. Compound 4 (Scheme 1B) was synthesized in two
steps; we first synthesized ((3-chloropropyl)sulfonyl)(palmitoyl)
amide by a coupling reaction between palmitic acid and 3-
chloropropane-1-sulfonamide. Next, trimethyl amine substi-
tuted chloride of ((3-chloropropyl)sulfonyl)(palmitoyl)amide to
afford compound 4. All synthesized compounds were purified
and characterized by 1H and 13C nuclear magnetic resonance
(NMR) and high-resolution mass spectrometry (HRMS) with
mass error <1 ppm as shown in Figure S-1-6 in the supporting
information, which indicated that compounds 1–4 are >99%
pure with the exception of compound 3 with ∼ 85% purity.
We formulated NEs (NE 1–5) using highly refined soybean
oil, ethanol, and water, emulsified with a non-ionic surfactant
and either compound 5, the prototype NE surfactant, or each
of the ZI surfactants (compounds 1–4) following a previously
optimized protocol.[6] The particle size distributions of the NEs
are considered important features of these formulations since
they require cellular uptake. We first measured the particle
diameter of each NE by dynamic light scattering (DLS) in a 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffer (HEPES,
pH∼7). The average particle diameters (Zave d) for all five NEs
are shown in Figure 2A. NE size distributions were unimodal
with low polydispersity (PdI< 0.25); however, the average
droplet size varied, ranging from 250 to 550 nm for 5 NE
formulations.
The size is within the range of NEs that have been shown
to be effective carriers in vivo, as reported earlier.[6] NEs 1 and 2
Figure 1. Compounds (1-5) used in (1-5) NE formulations.
Scheme 1. Synthetic route of compounds A) 3 and B) 4.
Figure 2. A) Size (Zave d nm) B) ζ-potential of NE formulations 1–5 consist of
compounds 1–5.
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showed a diameter ∼ 276 nm. NEs 3, 4 and 5 had sizes of 486,
531 and 466 nm respectively. Next, we measured the ζ-
potential of 5 NE formulations. The NE ζ-potential measure-
ments showed values that ranged from   36 mV to +53 mV as
presented in Figure 2B. As expected, given the charges on each
of the ZI, NEs 3 and 4 showed slightly negative (-9.5�6.8 mV)
and neutral (0.11�3.9 mV) charges, respectively. NEs 1 and 2
showed negative charges of   36.2�6.6 and   23.1�4.0 mV
respectively, whereas 5 had a positive charge of 52.7�5.2 mV.
Negative ζ-potential values were also observed for similar ZI (1
and 2) micelles by Priebe et al. as sulfobetaine and phosphor-
ylcholine preferentially incorporate anions rather than cations
in the interfacial region, resulting in an anionoid micelle.[16]
The induction of a moderate degree of cytotoxicity induced
by pathogens or carriers are associated with activation of
innate immunity and inflammation.[17] Therefore, we screened
the NEs 1–5 for cytotoxicity with KB cells. Previous studies
reported that cell types had very little impact on the relative
cytotoxicity of each NE, and the trends in the half maximal inhi-
bitory concentration (IC50) values observed in one cell type
were similar to all others.[6] Toxicity was evaluated in either
100% cell media or a 1:1 mixture of Opti-MEM and cell media
(V:V) over a 50,000-fold range of NE concentrations. From these
studies the 50% inhibitory concentration for each formulation
was identified after 24 hours of NE exposure, employing a XTT
cell viability assay (Figure 3). NEs 3 and 4 showed no detectable
cytotoxicity in any NE concentration tested with either 100%
cell media or the 1:1 mixture of Opti-MEM and cell media. NEs
1 and 2 showed no detectable cytotoxicity in 100% cell media
at any tested NE concentration. However, both (NEs 1 & 2)
showed an IC50 of ∼ 0.21% and 0.17% NE concentration
respectively in the mix of cell media and Opti-MEM. NE 5
containing the cationic surfactant (compound 5) showed IC50
of 0.16% and 0.08% NE concentration respectively in 100%
media and the mixture of Opti-MEM and cell media. Overall
these cytotoxicity studies in KB cells showed that NEs (1-4) that
consist of ZI surfactants (compounds 1–4) are either not
cytotoxic (NEs 3–4), or less cytotoxic (NEs 1–2) than NE 5
containing the cationic surfactant (compound 5).
To determine the interaction between NE and plasmid/
antigen (OVA), we measured particle size and surface charge,
by DLS and ZP measurement, after the addition of plasmid/
OVA at various concentrations to the NEs (1-5). The mixture
(NE+plasmid/OVA) of NEs 1–3 didn’t show any noticeable
change in size and ζ-potential with increasing concentrations
of plasmid or OVA. However, Figure 4A and 4 C showed that
Zave increased for the NE+plasmid/OVA mixture of NEs 4 and
5, over the same plasmid or OVA concentration range,
indicating complex formation with NEs 4 and 5. Additionally, as
the concentration of negatively charged plasmid and OVA
increases in the mixture, ζ-potentials for plasmid/OVA and NEs
4/5 mixture decreased as shown in Figures 4B and 4D which
further confirmed the incorporation of plasmid and OVA to the
NE formulations 4 and 5. Interestingly, the magnitude of the
particle size increase for the complex of NE 5 with OVA was
much greater than that of NE 4 with OVA, as the concentration
of OVA was increased, this is likely due to the formation of
aggregates as the NE cationic charge becomes neutralized
upon complex formation. There is a statistically significant
difference between group means of Zave/ζ-potentials of mixture
(NE+ plasmid/OVA) as determined by one-way ANOVA (p <
0.05) and shown by */**/***/**** with an exception between
group means of NEs 4 and 5 (not significant). Size distributions
were unimodal with low polydispersity (PdI< 0.25).
Next, the DNA transfection efficacy of these five formula-
tions (NEs 1–5) was tested on KB cells using a luciferase
expression plasmid as the reporter system. Luciferase expres-
Figure 3. NE formulations induced cytotoxicity for KB cells by NEs 1–5 in A)
100% cell media, B) 1:1 mixture of Opti-MEM and cell media.
Figure 4. NE and plasmid interaction studies: A) size distribution and B) ζ-
potential of 0.015% NEs (1-5) alone (control) or incubated mixture of 0.015%
NEs (1-5) and 0.6, 0.3 and 0.15 ng/mL plasmid respectively in the measured
solution. NE and OVA interaction studies: C) size distribution and D) ζ-
potential of 0.1% NEs (1-5) alone (control) or incubated mixture of 0.1% NEs
(1-5) and 0.8, 0.2 and 0.05 mg/mL OVA respectively in the measured solution.
There is a statistically significant difference between group means as
determined by one-way ANOVA (p < 0.05) with an except between group
means of NEs 4 and 5 (not significant). Size distributions were unimodal with
low polydispersity (PdI< 0.25).
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sion was measured as relative light units (RLU) in KB cells
transfected with NEs 1–5 in a 1:1 mixture of Opti-MEM and cell
media (V:V) at various NE concentrations. These experiments
were performed in a 1:1 mixture of Opti-MEM and cell media
(V:V) because initial studies showed that a higher transfection
efficacy was achieved in this mix than in undiluted cell media
which contains serum. These results were analyzed by one-way
ANOVA which showed that transfection efficacies achieved by
NEs 4 and 5 at different concentrations were significantly
different from that of NEs 1–3 (p < 0.05). However, there was
no statistically significant differences between group means of
the transfection efficacies of NEs 4 and 5 at different
concentrations as determined by one-way ANOVA. Similarly,
the transfection efficacies of NEs 1–3 are not statistically
significantly different. To further confirm the trend of trans-
fection by NEs 1–5 at different concentrations in KB cells, we
measured the total cell lysate protein concentration (μg/mL,
Figure S-7 in the supporting information) and calculated RLU/
μg protein. Figure 5B displays the RLU/ug protein vs % NE and
indicates a similar trend to what was seen in our transfection
data (Figure 5A).
Results indicate that NEs 4 and 5 achieved the highest
transfection efficacies, with NE 5 having the highest trans-
fection efficacy, ∼ 30% higher than that of NE 4, at 0.05% NE
concentration. This trend is reversed (6% lower) at 0.1% NE
concentration. NEs (1-5) consist of ionic surfactants (com-
pounds 1–5) and the same nonionic surfactants at the same
ratios (W:W) were produced following previously optimized
protocol. Interestingly, because the molecular weight of
compound 4 is 1.23 times higher than that of compound 5, the
molar concentration of compound 4 was ∼19% less than that
used with compound 5 in NEs 4 and 5 formulations
respectively. NE 5, which showed the highest efficacies at
0.05% and 0.1% NE concentration respectively, fell off at the
highest NE concentration, presumably due to cell toxicity. We
also noticed that NE 4 showed the lowest transfection efficacy
at 0.2% NE concentration. This led us to speculate that besides
toxicity, other factors may be involved because no noticeable
toxicity of NE 4 was observed at that concentration. In contrast
to this, NEs 1–3, consisting only of a ZI head group, showed
much lower transfection efficacies than NEs 4 and 5. There was
no difference in transfection with either NEs 1 or 2, even
though NE 2 has a positive outer layer whereas NE 1 has a
negative charge in the outer layer; yet both showed negative
ζ-potential. While NEs 1 and 2 showed minimal cytotoxicity at
higher concentrations as compared to NE 5, the most
interesting result is with NE 4. This compound is comprised of a
ZI head with a positive charge in the outer layer that showed
neutral ζ-potential and no cytotoxicity, but its higher cellular
uptake resulted in high transfection efficacy. In contrast, NE 3
with a ZI head that has a positive charge in the outer layer with
additional hydrophobicity due to the presence of an aromatic
ring showed slightly negative ζ-potential and no cytotoxicity,
but despite this it had minimal cellular uptake and transfection
efficacy.
Antigen uptake by epithelial and antigen presenting cells is
critical for immunogenicity of carriers through antigen process-
ing and presentation. Since NEs 4 and 5 showed high trans-
fection efficacies in KB cells, we evaluated their ability to
facilitate cellular uptake of a protein antigen in mouse lung
epithelial cells. The ability of NEs 4 and 5 to enhance antigen
uptake was evaluated in the TC-1 cell line. To differentiate
intracellular uptake from simple cell adhesion, a self-quenched
fluorescently labelled OVA (DQOVA) was employed as the
antigen. The DQOVA fluorescence remains quenched until the
antigen undergoes proteolytic processing inside the cell in the
endosome. The optimal NE concentration range for uptake
enhancement was identified for both NEs 4 and 5 and the
intracellular location of the antigen was confirmed by confocal
fluorescence microscopy (Figure 6). However, NEs 2 (Figure S-8
in supporting information) and control (Figure 6 I) showed no
cellular uptake in KB cells.
In conclusion, this work demonstrates that NE 4, consisting
of ZI surfactants, can effectively mediate cellular uptake of
antigen despite not having cytotoxicity as compared to cationic
emulsions (NE 5). The engineering of this unique molecule
(compound 4), consisting of a hydrophobic tail and ZI head,
with a positive charge in the outer layer could be a promising
approach to enhance the carrier efficacy while improving
tolerability. However, NE 3 that has positive charge in the outer
layer with additional hydrophobicity due to the presence of an
Figure 5. A) NE induced transfection by NEs 1–5 at different concentrations
in KB cells in a 1:1 mixture of Opti-MEM and cell media (V:V) over a 50,000-
fold range of NE concentrations. There is a statistically significant difference
between group means as determined by one-way ANOVA (p < 0.05) and
shown by **/*** except between group means of NE 4 and 5 (not significant).
B) RLU/μg protein vs % NE induces transfection by NEs 1–5 at different
concentrations in KB cells in a 1:1 mixture of Opti-MEM and cell media (V:V)
over a 50,000-fold range of NE concentrations.
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aromatic ring had minimal cellular uptake and transfection
efficacy. This study demonstrates the potential implications for
developing a nontoxic, next generation, carrier for nano-
emulsion-based vaccines.
Supporting information summary
The detail experimental procedures of DLS and transfection
studies, synthesis of surfactants, preparation of nanoemulsions
are given in the supporting information. Supporting informa-
tion also provides NMR and mass spectra of surfactants
(Figure S1-S6), the image corresponds to antigen uptake by NE
2 (Figure S7) and the graph corresponds to total cell lysate
protein concentration of NE induced transfection by NEs 1–5 at
different concentrations (Figure S8).
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